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SeOBJECTIVES The study sought to investigate the association between soluble growth stimulation expressed gene 2
(sST2) level and adverse outcomes in acute heart failure (HF).
BACKGROUND Several studies have demonstrated the prognostic utility of sST2 levels in HF.
METHODS sST2 levels were measured in sequential baseline and follow-up (48 to 72 h and 30 days) plasma samples
from 858 acute HF subjects enrolled in the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decom-
pensated Heart Failure) trial biomarker substudy and were related to in-hospital and post-discharge clinical outcomes.
RESULTS Higher sST2 levels were associated with increased death risk at 180 days (baseline hazard ratio [HR]: 2.21;
follow-up HR: 2.64; both p < 0.001). These results were not independent of covariates and aminoterminal pro–B-type
natriuretic peptide for baseline sST2 (HR: 1.29, p ¼ 0.243), but were borderline signiﬁcant for follow-up sST2 (HR: 1.61,
p ¼ 0.051). Subjects with persistently high (>60 ng/ml) sST2 levels at follow-up had higher 180-day death rates than
those with lower follow-up sST2 levels (adjusted HR: 2.91, p ¼ 0.004). Neither baseline nor follow-up sST2 levels were
associated with dyspnea improvement. Changes in sST2 from baseline were less in the nesiritide versus placebo group at
follow-up, but were similar at 30 days.
CONCLUSIONS Elevated levels of sST2 were associated with an increased risk of adverse clinical events in acute HF,
but prognostic value of baseline sST2 diminished after adjusting for clinical covariates and aminoterminal pro–B-type
natriuretic peptide. In those with elevated baseline sST2 levels, persistently elevated sST2 levels at follow-up were
associated with increased mortality risk. In addition, nesiritide did not demonstrate an incremental impact on sST2 levels
over standard therapy. (J Am Coll Cardiol HF 2016;4:68–77) © 2016 by the American College of Cardiology Foundation.m the *Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; yDepartment of Mathematics, Cleveland State
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AB BR EV I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
HF = heart failure
HR = hazard ratio
IQR = interquartile range
NT-proBNP = aminoterminal
pro–B-type natriuretic peptide
OR = odds ratio
sST2 = soluble growth
stimulation expressed gene 2
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69G rowth stimulation expressed gene 2 (ST2) isa transmembrane protein and a member ofthe Toll-interleukin 1 receptor superfamily
(1,2). ST2 binds interleukin-33 in response to cardiac
disease or injury and elicits a cardioprotective effect
by mitigating the maladaptive responses of the
myocardium to overload states (3,4). A truncated sol-
uble form of ST2 (soluble ST2 [sST2]) competes with
the membrane-bound form in this interleukin-33
binding. Elevated levels of sST2 signal the presence
and severity of adverse cardiac remodeling and tissue
ﬁbrosis, which may occur in response to an acute
coronary syndrome event or worsening heart failure
(HF) (3,5). Higher levels of sST2 are associated
with more severe clinical symptoms and with other
objective measures of HF severity, such as higher
C-reactive protein, higher natriuretic peptide levels,
lower left ventricular ejection fraction, and higher
diastolic ﬁlling pressures (6–12). Elevated circulating
sST2 levels have been associated with an increased
risk for mortality and sudden cardiac death in outpa-
tients with HF (9,13–15), as well as in acute HF (16).
However, most studies have only measured sST2
at a single timepoint (predominantly at baseline)
and only described the relationship with long-term
all-cause mortality.
In this post-hoc study utilizing blood specimens
collected serially in the ASCEND-HF (Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated
Heart Failure) trial, we examined the relationship
between baseline and serial levels of sST2 and dys-
pnea status, hospitalization (at 30 days), and death
(at 180 days). We also examined the effect of nesiri-
tide therapy on sST2 levels, hypothesizing that the
vasodilatory effects of nesiritide may relieve volume
overload more effectively than a placebo, thereby
potentially achieving greater reduction in sST2 levels.
METHODS
STUDY POPULATION. Details of the ASCEND-HF
Trial (NCT00475852) have been described elsewhere
(17). Brieﬂy, this was a multinational, multicenter,has received research grant support from Johnson & Johnson, Roche Diagn
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received advisory board funding from St. Jude Medical (modest) and Roch
Research and Development, LLC (formerly Johnson & Johnson). Dr. McMurra
& Johnson (signiﬁcant). Dr. Armstrong has received research grant support
cant). Dr. O’Connor has received research grant support from Johnson & Joh
and Roche Diagnostics; and has served as a consultant for Cardiorentis. Dr. St
Johnson (modest); consultant/advisory board for Johnson & Johnson (modes
relationships relevant to the contents of this paper to disclose. John R. Teer
Manuscript received October 8, 2014; revised manuscript received July 17, 2prospective randomized controlled trial of
7,141 subjects presenting with signs and
symptoms of acute decompensated HF
comparing nesiritide (a recombinant B-type
natriuretic peptide with vasodilatory prop-
erties) to placebo added to standard care. In
our study cohort, 858 subjects (12% of the
total population) consented to participate in
the biomarker substudy. A large majority of
subjects in the biomarker substudy were
recruited from North American sites (n ¼
824). Compared to the rest of the North
American study cohort (n ¼ 2,419), there were no
differences in race (p ¼ 0.422), heart rate (p ¼ 0.157),
atrial ﬁbrillation (p ¼ 0.124), blood urea nitrogen (p ¼
0.384), creatinine (p ¼ 0.499), time to randomization
(p ¼ 0.051), or beta-blockers (p ¼ 0.073). Neverthe-
less, age (66.6  14.9 vs. 64.5  15.4 years, p ¼ 0.001)
and left ventricular ejection fraction (31.6  15 vs.
30.4  15, p ¼ 0.035) were signiﬁcantly different.
STUDY DESIGN. The intent of the biomarker substudy
was to collect venous blood samples at randomization
(“baseline”), 48 to 72 h following randomization, and
at the 30-day follow-up visit. Blood samples were
collected in ethylenediaminetetraacetic acid-plasma,
immediately centrifuged at the study sites, and
stored at –80C for subsequent analysis at a central
core laboratory. Aminoterminal pro–B-type natri-
uretic peptide (NT-proBNP) levels were determined
by the VITROS NT-proBNP Assay (Ortho-Clinical Di-
agnostics, Raritan, New Jersey).
SOLUBLE ST2 ASSAY. Plasma sST2 levels were
measured by the Presage ST2 Assay (Critical Di-
agnostics, San Diego, California) at a College of
American Pathologists/Clinical Laboratory Improve-
ments Amendments-approved core laboratory inde-
pendent of the sponsors. This is a quantitative
sandwich enzyme-linked immunosorbent assay using
a mouse monoclonal antihuman sST2 capture anti-
body on microtiter plate wells and a second bio-
tinylated mouse monoclonal antihuman sST2 tracer
antibody with a measuring range of 3.1 to 200 ng/mlostics, Critical Diagnostics, and BG Medicine (signif-
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detection is at 1.8 ng/ml, and the limit of quantiﬁca-
tion at 2.4 ng/ml.
CLINICAL ENDPOINTS. The following adjudicated
endpoints were analyzed: 30-day death, 180-day
death, 30-day HF hospitalization or death, and the
composite of persistent or worsening HF or death from
any cause. We also used the ASCEND-HF trial’s copri-
mary dyspnea endpoint (moderately or markedly
improved relative to the time of randomization
measured by a 7-point Likert-type scale at 6 or 24 h) to
assess the association between sST2 levels and symp-
tom relief.
STATISTICAL ANALYSES. Clinical characteristics are
presented as a percentage (%) for categorical vari-
ables, mean  SD for normally distributed contin-
uous variables, and median (interquartile range
[IQR]) for non-normally distributed continuous var-
iables. The Cochran-Armitage test was used to test
for trend in baseline characteristics across increasing
tertiles of sST2 at baseline. Survival curves are
estimated for each group, considered separately,
using the Kaplan-Meier method and compared sta-
tistically using the log-rank test. The association
between sST2 and outcomes was performed using
both univariate and multivariate logistic regression
analysis (for 30-day outcomes) or Cox proportional
hazards analysis (for 180-day mortality). Logistic
regression was used in the analyses of dyspnea
improvement. sST2 and NT-proBNP were both log
transformed, and odds ratios (ORs) and hazard ra-
tios (HRs) were analyzed using increments of sST2/
NT-proBNP per log increase in sST2. For the multi-
variate analysis, we adjusted the covariates identi-
ﬁed from the overall ASCEND-HF study population
to be prognostically relevant (the ASCEND-HF
risk model) (Online Table 1). We used the robust
covariance matrix estimates to adjust the variance-
covariance matrix of both logistic regression and
Cox models to correct for correlated responses from
cluster (multicenter) samples (18). To assess if the
addition of sST2 to the ASCEND-HF risk model with
NT-proBNP improves outcome prediction, we used
the category-free net reclassiﬁcation index by the
Pencina method (19,20). Levels of sST2 at all time
points and changes in sST2 from baseline were
compared between subjects receiving nesiritide and
placebo using the Wilcoxon rank sum test or Stu-
dent t test. All statistical analyses were performed
using Stata 13.1 software (StataCorp LP, College
Station, Texas) and R 3.1.0 (Vienna, Austria). A
2-sided p value of <0.05 was considered statistically
signiﬁcant.RESULTS
PATIENT CHARACTERISTICS. Baseline characteris-
tics of the study population are illustrated in Table 1.
The median time between presenting to the hospital
and randomization (baseline) was 16 h. In our study
cohort, median sST2 levels were 71.2 (IQR: 48.2 to
111.1) ng/ml at baseline, decreasing to 46.9 (IQR: 32.4
to 70.3) ng/ml at 48 to 72 h and 39.5 (IQR: 27.8 to 63.8)
ng/ml at 30 days. In other words, 89% (763 of 858) of
patients had sST2 levels above the diagnostic cutoff
value of 35 ng/ml for chronic HF. Subjects with
impaired or preserved left ventricular ejection frac-
tion had similar levels of baseline sST2 (72.4 [IQR:
49.2 to 116.0] ng/ml vs. 68.9 [IQR: 45.1 to 108.3] ng/ml;
p ¼ 0.178, respectively).
BASELINE sST2 LEVELS AND PROGNOSIS. There
were 24 (2.8%) deaths and 77 (9.2%) HF rehospitali-
zations by 30 days, and 97 (11.4%) deaths by 180 days.
Higher baseline sST2 level was associated with a
higher risk of death at 30 days (OR: 2.33; 95% conﬁ-
dence interval [CI]: 1.05 to 5.19; p ¼ 0.038) and at
180 days (HR: 2.21; 95% CI: 1.56 to 3.13; p < 0.001),
as well as death/worsening HF before discharge
(OR: 2.23; 95% CI: 1.28 to 3.90; p ¼ 0.005) (Table 2).
Figure 1A shows that increasing quartiles of baseline
sST2 was associated with greater 180-day mortality
risk by Kaplan-Meier estimates. In contrast, symp-
tomatic relief at 6 h and at 24 h was not associated
with higher levels of baseline sST2 (p > 0.29, data not
shown). After adjusting for other risk covariates in the
ASCEND-HF risk model, only 180-day mortality risk
was associated with higher levels of baseline sST2
(adjusted HR: 1.79; 95% CI: 1.22 to 2.62; p ¼ 0.003
(Table 2). However, further adjustment with the
ASCEND-HF risk model plus baseline NT-proBNP
levels demonstrated that the prognostic value of
baseline sST2 was no longer signiﬁcant (Table 2, as
dichotomous variables in Online Table 2); this was
true despite the fact that adding baseline sST2 to the
ASCEND-HF risk model, plus baseline NT-proBNP,
correctly reclassiﬁed 10.76% of subjects for the
180-day death endpoint (with 8.64% events correctly
classiﬁed and 2.12% nonevents correctly classiﬁed)
(Online Table 3A). Interestingly, interaction testing
between baseline sST2 and baseline NT-proBNP
was statistically signiﬁcant only for the 30-day
death/HF rehospitalization endpoint in both unad-
justed (p ¼ 0.03) and adjusted (p ¼ 0.02) models
(Online Table 4). Speciﬁcally, there was a positive
association between baseline sST2 and outcomes for
high (above median) baseline NT-proBNP, and a
negative association between sST2 and outcomes for
TABLE 1 Baseline Characteristics
Baseline sST2
Total
(n ¼ 858)
Quartile 1
(n ¼ 215)
Quartile 2
(n ¼ 214)
Quartile 3
(n ¼ 214)
Quartile 4
(n ¼ 215) p Value
Range, ng/ml <48.2 48.2–71.2 71.2–111.1 $111.1
Age, yrs 65.5  15.2 62.27  15.48 64.6  14.4 68.3  14.82 66.9  15.5 <0.001
Female, % 31.6 37.7 34.1 26.6 27.9 <0.001
White, % 67.8 60.5 67.8 69.6 73.5 <0.001
Systolic BP, mm Hg 127.3  19.9 129.3  21.4 129.9  21.1 126.2  18.8 123.8  17.4 0.004
Heart rate, beats/min 80.2  16.3 80.2  14.3 79.5  17.4 80.0  17.0 81.1  16.3 0.896
Atrial ﬁbrillation, % 41.3 32.1 36.9 52.3 43.7 <0.001
Hypertension, % 78.3 83.3 81.3 75.2 73.5 <0.001
BUN, mg/dl 28.3  16.8 24.0  13.0 26.5  15.9 30.7  19.1 32.0  17.5 <0.001
Creatinine, mg/dl 1.44  0.6 1.34  0.5 1.37  0.5 1.49  0.61 1.54  0.6 <0.001
Sodium, mmol/l 138.6  4.0 138.9  3.5 139.3  3.6 138.7  3.8 137.6  4.6 0.004
NT-proBNP (n ¼ 752), pg/ml 5,545
(2,856–11,097)
2,917
(1,368–6,370)
4,616
(2,894–9,372)
6,134
(3,538–11,357)
9,388
(5,291–14,839)
<0.001
LVEF, % 26 (20–40) 30 (20–40) 26 (20–40) 25 (20–40) 25 (20–40) 0.280
Time from presentation
to randomization, h
16.3  9.4 17.26  10.78 16.29  8.74 14.45  8.32 17.15  9.27 0.387
Ischemic etiology, % 60.3 55.3 60.3 62.1 63.3 <0.001
Beta-blockers, % 75.3 73.0 74.8 77.6 75.8 <0.001
ACEi or ARB, % 64.7 65.1 67.3 62.1 64.2 <0.001
MRA, % 23.8 23.3 24.8 22.4 24.7 <0.001
Values are mean  SD or median (interquartile range), unless otherwise indicated. All p values were from test of trend (Jonckheere-Terpstra test for continuous and Cochran-
Armitage test for categorical variables).
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BP ¼ blood pressure; BUN ¼ blood urea nitrogen; LVEF ¼ left ventricular ejection
fraction; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ aminoterminal pro–B-type natriuretic peptide; sST2 ¼ soluble growth stimulation expressed gene 2.
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71low baseline NT-proBNP (Online Figure 1). In con-
trast, there was no interaction between baseline sST2
and NT-proBNP for the 180-day death endpoint
(p ¼ 0.77) (Online Table 3). In particular, those withTABLE 2 Baseline sST2 Levels and Adverse Clinical Outcomes and Int
Model 30-Day Death p Value
30-D
Reho
Baseline sST2
Univariate model 2.30 (1.15–4.74) 0.019 1.67
Adjusted model 1 1.95 (0.91–4.16) 0.085 1.37
Adjusted model 2 1.52 (0.66–3.50) 0.324 1.07
Event rates 24/856 (2.8) 82
48–72-h follow-up sST2
Univariate model 1.85 (0.81–4.20) 0.145 2.11
Adjusted model 1 1.47 (0.61–3.59) 0.387 1.52
Adjusted model 2 1.07 (0.40–2.86) 0.889 1.32
Event rates 16/662 (2.4) 82
30-day follow-up sST2†
Univariate model — —
Adjusted model 1 — —
Adjusted model 2 — —
Event rates — —
Values are odds ratio (95% conﬁdence interval) or n/N (%). Both sST2 and NT-proBNP we
(Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial
NT-proBNP (with corresponding time point). †All deaths before 30 days were excluded
HF ¼ heart failure; other abbreviations as in Table 1.both elevated baseline sST2 and baseline NT-proBNP
(stratiﬁed by their median values) portended the
highest 180-day mortality risk (Online Figure 2).
Cubic spline analyses also supported the linearity oferactions With the ASCEND-HF Trial Risk Model and NT-proBNP
ay Death/HF
spitalization p Value 180-Day Death p Value
(1.17–2.39) 0.005 2.21 (1.57–3.13) <0.001
(0.93–2.02) 0.117 1.91 (1.33–2.72) <0.001
(0.68–1.67) 0.775 1.35 (0.90–2.03) 0.145
/667 (12.3) 97/858 (11.3)
(1.42–3.13) <0.001 2.64 (1.82–3.84) <0.001
(0.98–2.37) 0.063 2.12 (1.42–3.16) <0.001
(0.82–2.12) 0.255 1.77 (1.14–2.74) 0.011
/667 (12.3) 97/858 (11.3)
— — 2.29 (1.46–3.62) <0.001
— — 2.29 (1.35–3.88) 0.002
— — 2.16 (1.22–3.80) 0.008
— — 41/589 (7.0)
re both log transformed, increments per log increase; adjusted model 1 ¼ ASCEND-HF
risk model according to endpoints (Online Table 1); adjusted model 2 ¼ Model 1 plus
from the 30-day follow-up analysis.
FIGURE 1 Kaplan-Meier Analysis for 180-Day Survival
Kaplan-Meier analysis for 180-day survival, stratiﬁed by quartiles of (A) baseline and (B) 48- to 72-h follow-up plasma soluble growth stimulation expressed gene 2
(sST2) levels. Baseline sST2 tertile ranges: Quartile 1 (Q1) ¼ <48.2 ng/ml; Quartile 2 ¼ 48.2 to 71.2 ng/ml; Quartile 3 ¼ 71.3 to 111.2 ng/ml; Quartile 4 ¼ >111.2 ng/ml.
48- to 72-h sST2 tertile ranges: Quartile 1 ¼ <32.4 ng/ml; Quartile 2 ¼ 32.4 to 46.8 ng/ml; Quartile 3 ¼ 46.9 to 70.3 ng/ml; Quartile 4 ¼ >70.3 ng/ml.
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72the 180-day mortality risk for baseline sST2 levels
(Figure 2A).
FOLLOW-UP sST2 LEVELS AND PROGNOSIS. At 48
to 72 h after enrollment, higher sST2 levels portend
increased risk of all-cause death at both 30 and 180
days, as well as death/rehospitalization at 30 days
(Table 2). Elevated follow-up sST2 was also associated
with increased risk of death/worsening HF before
discharge (OR: 2.41; 95% CI: 1.25 to 4.63; p ¼ 0.008).
After adjustments for the ASCEND-HF risk model,
the prognostic signiﬁcance of follow-up sST2 levels
was only relevant for 180-day death, and remained
borderline signiﬁcant with the addition of baseline
NT-proBNP to the ASCEND-HF risk model (adjusted
HR: 1.61; 95% CI: 1.00 to 2.60; p ¼ 0.051) (Table 2).
Examining the Kaplan-Meier curves revealed that
the divergence of 180-day mortality risk occurred
between the third and fourth quartile of the 48- to
72-h follow-up sST2 level (71.2 ng/ml). Furthermore,
adding 48- to 72-h follow-up sST2 to the ASCEND-HF
risk model, plus follow-up NT-proBNP, correctly
reclassiﬁed 15.6% of subjects for the 180-day death
endpoint (with 13.85% events correctly classiﬁed
and 1.75% nonevents correctly classiﬁed; Online
Table 3B). Cubic spline analyses supported the line-
arity of the risk at follow-up (Figure 2B). In addition,
30-day follow-up sST2 levels also provide incre-
mental prognostic value in either of the adjusted
models (Table 2, Online Figure 3), with similar
modest reclassiﬁcation to the 48- to 72-h follow-up
data (Online Table 3C).CHANGES IN sST2 LEVELS AND PROGNOSIS. Among
the 858 subjects in the biomarker substudy, 680 had
samples for both baseline and 48 to 72 h time points.
Compared to baseline, an overall 64.4% and 51.6%
reduction in absolute levels of sST2 levels occurred at
48 to 72 h and at 30 days after randomization,
respectively. The median absolute change in sST2
from baseline to 48 to 72 h was –22.80 (IQR: –44.70 to
–6.44) ng/ml. At 48 to 72 h, there was no lowering of
sST2 absolute levels from baseline in 14.4% of sub-
jects; this was associated with poorer outcomes,
including 30-day death/HF readmission (OR: 2.50;
95% CI: 1.45 to 4.32; p ¼ 0.001) and 180-day death
(HR: 1.98; 95% CI: 1.15 to 3.42; p ¼ 0.013) when
compared with subjects showing any decrease in
sST2 (Figure 3). After adjustments for the ASCEND-
HF risk model and baseline NT-proBNP, the prog-
nostic value of the lack of sST2 lowering at 48 to 72
h from baseline was signiﬁcant for the outcome of
30-day death/HF readmission (adjusted OR: 1.94;
95% CI: 1.01 to 3.72; p ¼ 0.046), but not for the
180-day death endpoint (adjusted HR: 1.27; 95% CI:
0.69 to 2.35; p ¼ 0.442). Because the combined
biologic/analytic variability for sST2 has been pre-
viously reported as w30% (21,22), we further de-
ﬁned a clinically relevant sST2 reduction as a >30%
decrease in sST2 levels from baseline to 48 to 72 h
(which occurred in 377 subjects, or 55%). Compared
to those with a #30% sST2 reduction, subjects who
demonstrated a >30% reduction in sST2 had lower
event rates in all endpoints except for 30-day death
(Online Figure 4).
FIGURE 2 Cubic Spline Curve
Cubic spline curve for (A) baseline; and (B) follow-up (48 to 72 hr)
sST2 levels associatedwith 180-day death. sST2¼ soluble growth
stimulation expressed gene 2.
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73To further examine whether there is a threshold of
follow-up sST2 level that conferred heightened risk,
Online Table 5 outlines the baseline characteristics
of subgroups according to changes from baseline to
48- to 72-h sST2 levels, stratiﬁed at a baseline median
sST2 level of 71.2 ng/ml (Online Figure 5 presents the
CONSORT diagram for subgroup distributions). In the
cohortwith elevated baseline sST2 levels (>71.2 ng/ml),
we further observed a 3-fold increase in 180-day mor-
tality risk between those with persistently high sST2
(>71.2 ng/ml) versus low (#71.2 ng/ml) at 48- to 72-h
follow-up (Figure 4, also Online Figure 6 for all sub-
groups); this ﬁnding remained statistically signiﬁcant
in multivariate analysis after adjusting for the
ASCEND-HF risk model and baseline NT-proBNP
(Table 3).CHANGES IN sST2 LEVELS AND TREATMENT. Over-
all, 502 subjects (257 assigned to nesiritide, 245
assigned to placebo) had samples collected at all 3
time points. There were no signiﬁcant differences in
baseline characteristics between the nesiritide and
placebo treatment groups, including similar mean
NT-proBNP levels (8,910  10,492 pg/ml vs. 8,968 
9,577 pg/ml; p ¼ 0.329). Both groups demonstrated a
signiﬁcant reduction in sST2 levels from baseline to
48- to 72-h follow-up, and further lowering of sST2
levels was observed at the 30-day visit in both groups
(Table 4). The absolute changes in sST2 from base-
line to 48 to 72 h was signiﬁcantly greater in the
placebo group than in the nesiritide group (respective
median absolute changes –26.11 ng/ml vs. –18.05 mg/l;
p ¼ 0.005), but the 2 groups did not differ by treat-
ment regarding absolute changes in sST2 from base-
line to 30 days (Table 4). Additionally, sST2 levels at
30-day follow-up and absolute changes in sST2 levels
from baseline to 30 days were similar between the 2
treatment groups (Table 4).
DISCUSSION
There are 4 major ﬁndings from this study. First, we
observed that baseline sST2 levels elevated in the
acute HF setting were comparable with earlier re-
ports (23–26), and were higher than those reported
in the chronic setting (cutoff at 35 ng/ml) (9,15).
Second, the prognostic ﬁndings for sST2 at baseline
for 180-day outcomes were generally neutral after
adjustments for the ASCEND-HF risk model and
NT-proBNP, despite the signiﬁcant univariate ﬁnd-
ings. In contrast, follow-up (48 to 72 h or 30 days)
sST2 appeared to provide incremental prognostic
value, albeit diminished following covariate and
NT-proBNP adjustments. Third, consistent with
previous reports sST2 levels tend to fall after med-
ical therapy (23,27,28), but we found that 1 in 7
patients demonstrated no fall in sST2 levels
following medical therapy. Meanwhile, persistently
elevated sST2 levels (above baseline median of 71.2
ng/ml), or lack of any lowering of sST2 levels
despite medical therapy, may deﬁne a higher-risk
subset of patients compared to those who demon-
strated a fall in sST2 level following medical ther-
apy as seen in a smaller series (23). Finally, contrary
to our hypothesis, nesiritide did not demonstrate
any signiﬁcant effects on lowering sST2 levels over
standard therapy in the long-term. Conversely, the
placebo group showed a greater fall in sST2 levels
from baseline to 48 to 72 h than the nesiritide
group, even though such difference did not extend
to the 30-day timepoint. Therefore, persistently
FIGURE 3 Comparison of Adverse Clinical Outcomes
Comparison of adverse clinical outcomes in patients with a decrease versus increase/no change in absolute levels of sST2. HF ¼ heart failure;
sST2 ¼ soluble growth stimulation expressed gene 2.
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74elevated sST2 following stabilization during acute
HF hospitalization may identify a higher risk cohort
even after clinical risk factors and NT-proBNP levels
have been considered.
The lack of incremental prognostic signiﬁcance
of baseline sST2 with the addition of NT-proBNP
levels to the standard ASCEND-HF risk model wasFIGURE 4 Serial sST2 Levels and Adverse Clinical Outcomes
Kaplan-Meier survival analysis stratiﬁed by high versus low baseline and f
small subset of subjects with low sST2 at baseline and elevated sST2 atunexpected, because previous studies have demon-
strated an incremental prognostic value of sST2
levels—even when adjusting for the levels of various
natriuretic peptide assays (6,16,29). Although there
are some inconsistencies between the Cox models
and the reclassiﬁcation analysis, it has been increas-
ingly recognized that the latter may in some casesollow-up (48 to 72 h) sST2 levels (cutoff at 71.2 ng/ml), excluding the
follow-up (n ¼ 15).
TABLE 3 HRs for Death at 180 Days by Change Trends in sST2 From Baseline to 48–72 h (Using Median sST2 of 71.2 ng/ml as Cutoff)
High Versus Low sST2 at Baseline;
Low at 48–72-h Follow-Up
High at Baseline; High Versus
Low sST2 at 48–72-h Follow-Up
Low/Low High/Low p Value High/Low High/High p Value
Unadjusted HR 1.0 1.03 (0.54–1.98) 0.924 1.0 3.01 (1.63–5.59) <0.001
Adjusted HR (model 1) 1.0 0.82 (0.42–1.59) 0.552 1.0 2.60 (1.38–4.89) 0.003
Adjusted HR (model 2) 1.0 0.66 (0.34–1.29) 0.226 1.0 2.42 (1.27–4.61) 0.007
Event rates 23/315 (7.3) 15/196 (7.7) 15/196 (7.7) 31/147 (21.1)
Values are HR (95% conﬁdence interval) or n/n (%).
HR ¼ hazard ratio; other abbreviations can be found in Table 1.
TABLE 4 Impact of Nesiritide Therapy on Absolute Changes in sST2 Levels
sST2 Levels (ng/ml)
Placebo
(n ¼ 245)
Nesiritide
(n ¼ 257) p Value
Baseline 70.69 (51.40 to 102.54) 69.24 (46.86 to 108.05) 0.567
48–72 h 42.13 (30.85 to 60.81) 48.46 (32.52 to 67.67) 0.067
30 days 39.25 (28.12 to 61.94) 39.74 (27.52 to 67.20) 0.590
Changes from baseline
to 48–72 h
–26.11 (–45.88 to –12.03) –18.05 (–41.20 to –4.37) 0.005
Changes from baseline
to 30 days
–26.26 (–52.10 to –6.13) –21.01 (–52.27 to –2.62) 0.26
p value from nonparametric test.
Abbreviations as in Table 1.
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75overestimate the incremental value of a biomarker
even in independent validation data (30). Interest-
ingly, many of the earlier studies that conducted
multivariate analyses had limited covariate(s) or sin-
gle cutoff values, and the majority of these studies
conducted utilized research-based assays (6,8,29).
Also, most previous studies had a more extended
period of follow-up beyond 180 days (6,8,16), and did
not include blood urea nitrogen, which is a widely
available and robust prognostic covariate (31).
Furthermore, in a clinical trial population such as the
ASCEND-HF trial, there were speciﬁc inclusion and
exclusion criteria, where a number of extreme phe-
notypes would have been excluded. The lower co-
morbidity in a clinical trial population than in single-
center observational cohorts and the cardiac
nonspeciﬁc nature of sST2 (7,21,32) might have also
tracked better with long-term adverse outcomes than
intermediate adverse outcomes following hospital
discharge from acute HF. Nevertheless, our ﬁndings
corroborate 2 recent post-hoc biomarker analysis
from well-characterized large clinical trials of chronic
HF, both of which observed that the prognostic value
of sST2 was less robust when natriuretic peptide
levels were included in the multivariate models
(9,33). In fact, recent studies that measure trans-
cardiac gradient of sST2 levels have even challenged
the cardiac origin of circulating sST2 (7,34). Because
natriuretic peptide testing is so widely available and
its clinical utility for diagnosis and prognosis in the
setting of acute HF has been well established, further
studies that explore the incremental value of sST2
testing in a multimarker strategy with natriuretic
peptides are warranted before broad clinical
adoption.
Because insights can be gained not only from the
absolute circulating ST2 levels, but from changes
following medical stabilization, we compared sub-
jects that did not show a reduction in sST2 levels (1
of 7 subjects in our cohort) versus subjects who
did. As reported in the published data, one of theadvantages of sST2 is the relatively low assay and
biological variability compared with other cardiac
biomarkers, which may favor its reliability in serial
testing (22,35). Previous studies have demonstrated
that either a 15% reduction in sST2 or a lower
sST2 ratio (<75%) within 2 weeks was observed
in destabilized HF patients with no subsequent
events compared to those with events (27). Our
sensitivity analyses (using both a clinically relevant
sST2 reduction of >30% or below a threshold
of 60 ng/ml) further demonstrate the prognostic
importance of lowering sST2 levels in those with
elevated baseline sST2, and a 4-fold increase in
mortality risk between those with sST2 levels above
versus below 60 ng/ml at 48- to 72-h follow-up
(Online Figure 4). The observed ranges were similar
to sST2 levels measured in a smaller cohort with
serial samples measured at baseline and at day 4 (23).
The lack of long-term differences in absolute
changes of sST2 levels over time between nesiritide
and placebo is consistent with the primary results
of the ASCEND-HF trial. In fact, the short-term
reduction in absolute levels of sST2 appeared to
be signiﬁcantly larger in the placebo group, even
though both groups achieved similar urine volumes
and similar median blood pressures or rates of
hypotension.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Elevated sST2 levels at follow-up, but not at baseline,
provided incremental prognostic value for 180-day
mortality beyond clinical covariates and natriuretic
peptide levels.
TRANSLATIONAL OUTLOOK: Further studies that
explore the incremental value and timing of sST2
testing in a multimarker strategy with natriuretic
peptides are warranted before broad clinical adoption.
In the interim, the lack of incremental reduction in
sST2 by nesiritide also calls into question the role of
myocardial stress as the underlying mechanisms of
sST2 generation in the setting of heart failure.
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76STUDY STRENGTHS. The strengths of this study
include: 1) meticulously collected serial samples in a
prospective biomarker study in a large representative
patient population; 2) adjudicated endpoints inclu-
ding HF rehospitalizations and dyspnea relief as part
of a multicenter randomized clinical trial; and 3) a
large study population compared to previous studies
using the Food and Drug Administration–cleared
assay.
STUDY LIMITATIONS. The number of events, rela-
tively small size of the study groups (particularly with
subgroup analyses), and relatively short (180-day)
mortality endpoint may have reduced the power to
detect the incremental prognostic value of sST2.
Given our present ﬁndings from this post-hoc anal-
ysis, the incremental value of sST2 testing in a mul-
timarker strategy with natriuretic peptides may
depend on the appropriate timing (at follow-up rather
than at baseline) and patient population (in those
with high rather than low NT-proBNP levels); this
should be further investigated. Furthermore, the
clinical relevance of assessing changes in sST2 should
be further investigated in these patient subsets.
CONCLUSIONS
Elevated levels of sST2 at baseline and follow-up
were associated with an increased risk of adverse
clinical events. However, the addition of baselinesST2 to a standard risk model plus NT-proBNP levels
did not improve the prediction of 180-day outcomes,
yet failure to lower sST2 levels portends a poor
prognosis. Nesiritide did not demonstrate any sig-
niﬁcant effects on lowering sST2 levels over standard
therapy.
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